Posters

      Plasma Protein Biomarker Identification For Monitoring Molecular Changes in Smokers, Former Smokers, and E-Vapor Product Users Relative to Never Smokers

      Nury, C.; Eb-Levadoux, Y.; Kolli, A.; Poussin, C.; Curran, T. M.; Baglia, L. A.; Berg, R. A.; Felber Medlin, L.; Ansari, S.; Kishazi, E.; Martin, F.; Titz, B.; Picavet, P.; Ivanov, N. V.; Spinelli, S. L.; Hoeng, J.; Peitsch, M. C.

      Conference date
      Oct 20, 2020
      Conference name
      HUPO conference
      Topic
      Summary

      Introduction: Inhaled toxicants present in cigarette smoke accelerate and exacerbate inflammation and oxidative stress. Over time, these processes increase the risk of developing respiratory and cardiovascular diseases.

      Developing alternative tobacco or nicotine products that have the potential to reduce the risk for smokers who would otherwise continue to smoke is one approach for addressing these health concerns. Electronic-vapor products (EVP) are proposed as potential reduced-risk products; however, their impact requires in-depth investigation. This study aimed to examine molecular profiles and biological networks that are perturbed by smoking, reversible upon smoking cessation, and largely unknown with respect to EVP use, to identify new biomarkers.

      Methods: Here, we present the plasma protein profiling data from this study. About 200 plasma samples were obtained from smokers (CS), former smokers (FS), and EVP users and compared with those from never smokers (NS). The samples were processed in randomized order by using Sample Preparation Kit Pro (Biognosys, Switzerland) and further analyzed on a UPLC coupled to a Q-Exactive HF by using the data-independent acquisition (DIA) mode after PQ500 spike-in.

      Results: To our knowledge, this study is the first human research study to use PQ500 spike-in combined with DIA analysis of human plasma. This approach allowed us to accurately quantify 140 proteins across the entire dataset by using Spectronaut software.

      Specific molecular changes associated with smoking and cessation were detected. The abundances of 14, 5, and 0 proteins were significantly different in plasma in the CS vs. NS, FS vs. NS and EVP vs. NS group comparisons, respectively.

      Conclusions: Integration of these data with other omics measurements as well as with demographics and EVP usage history is expected to support potential risk reduction in adult smokers who switched to EVP or quit smoking.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.